Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bright Minds Biosciences Inc

29.25
-2.7900-8.71%
Volume:28.70K
Turnover:865.29K
Market Cap:206.04M
PE:-192.72
High:31.84
Open:30.61
Low:29.24
Close:32.04
Loading ...

Company Profile

Company Name:
Bright Minds Biosciences Inc
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
- -
Office Location:
19 Vestry Street,New York,New York,United States
Zip Code:
10013
Fax:
- -
Introduction:
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Directors

Name
Position
Ian McDonald
President, Chief Executive Officer and Director
Jan Pedersen
Director and Chief Science Officer
David Weiner
Director
Jeremy Fryzuk
Director
Nils Christian Bottler
Director

Shareholders

Name
Position
Ian McDonald
President, Chief Executive Officer and Director
Ryan Cheung
Chief Financial Officer
Jan Pedersen
Director and Chief Science Officer
Mark A. Smith
Chief Medical Officer